KARPAS 299 Human Non-Hodgkin’s Ki-positive Large Cell Lymphoma cell line useful in oncology research, developed at the University of Cambridge.

Publications:

Ficsher et al. (1988). Blood 72, 234–240

Wolke et al. (2006). Int J Mol Med 17, 275–278

Drexler et al. (2004). Leukemia 18, 1569–1571

Fillmore et al. (2002). FEBS Lett. 522, 183-188

Cambridge Enterprise Limited is the exclusive licensor for the Karpas cell line portfolio. We have partnered with ECACC (The European Collection of Cell Cultures; a Public Health England Culture Collection) to manage distribution of the majority of these cells on our behalf. Enquires to either organisation are welcomed.